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(5), stroke(4)and heartdisease(2). Ourfindingsdo not supportthe belief
that the tX is a commoncauseof MHTamongstwomenof childbearing











hadan initialserumcreetinine(Cr) <300 wmolfl.Aftera medianfollow-up
of 53months(IQR15-103),51.6%(9W187)patientsdemonstrateda risein
serumCr.Patientswithan initialserumCr -=300wmol/1(Group1, n = 136)
wereoomparadwiththosewithCr>300 mmoWl(Group2, n=33); andthose
withan overallrfaein serumCr (GroupA, n = 38)werecomparedto those
withnorfseor a fallat follow-up(GroupB,n =91).
Results:mean@d.)
GrouP1 Group2 GroupA &ouP B
Aoe fV6WS) 49.5 [t4.o) 4s.s(10.3) 49.8(13.5) 4s.9 (13.0).g- ., .,
DurstfonofpriorHT(mths) 30.8 (58.3j 27.3(45.0) 33.6 (57.0) 25.6(54.5)
Inftfalurea (mmo!41) S.4 (3.7) 27.4 (16.S)” Io.e (9.7) 13.7 (12.5)
Initialcraatlne (Cr) (~mofll) 153 (58.6) 665 (450” 204 (155) 31s (399)+
SW atpraaan~tlon (mmHg) 230.0 (27.1) 328.8 (30.S) 230.1(29.2)229.3(25.8)
DBP at fxesentatlon(mmHg) 143.1 (19.6) 144.S (16.5) 143.8(20.3) 143,0 (17.4)
Follow-upurea (mmolrl) 11.7 (10.0) 29.7 (19.2)- 17.s (1s.5) 11.5 (8.7)+
Follow-upCreatinine (pmolll) 243 (295) 678 (333)* 409 (405) 223 (214)+
Follow-uPSBP (mmHg) 150.1 (30.5) 1s0.5 (3S.9)+ 170.0 (32.8) 156.0 (32.2)+
Fdlow-up DBP (mmHg) 95.6(17.3) 103.4(15.7)”” 100.2 (17.4) 93.0 (17.6)+
Follow-upduration(mtha) 70.1 (58.6) 33.4 (48.1)’ 61.9 (59.0) S4.4 (57.9)




ureaor Cr whencomparedto initial levels(pairedt-test,p = NS).In Group
1,therewasamarkeddeteriorationin renalfunctionat follow-up(meanrise
in serum Cr SO #moVt, Seruiw urea 3.3 mmolll; both p < 0.0001). Group2
patientshada lowermediansurvivalcomparedwithGroup1 (15monthsvs
59months,Lae-Deaustatistic=15.4,p=0.0001).Patientswithdeteriorating
renalfunction(GroupA) had higherinitial serumCr levelsand follow-up
BPswhencomparedto GroupB.Wesuggestthat renalfunctioncontinues













Thersautteof the EMIATtrialhaveshowna significantreduotionof arrhyth-
mia cardiacdeathsin post myocardialinfarctionpatients<75 yearswith




availablein 1181EMIATpts,a meannormal-to-normalRRintervals 850ms
(meansinusrhythmheartrate>--92 bpm)waspresentin74pts(20female,
meanage80.4& 9.9years).Of these,36 and38 werein the Amiodarone
andPlacebogroup,respectively.IntheAmiodaroneandPlacebogroupwith
increased 24-hour heart rate, there were 10 and 17deathsduringthe2 year
follow-up,respectively(27.8%vs447%). Cumulativesurvivorcufvesof pa-
tientswithincreasedmeanheartrateshowedclearseparation(Fig.:full line
= Amiodarone group,dashedline= Placebogroup)butbecauseof thesmall
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vlvorsofMl(meanage60+ 7yeara;Ml >6 monthsprevious)werescreened
forelevatedCptitres(lgG> 1/84)usingthemlcroimmunofluorescencet st.
60 eligiblepatientswererandomisedintoa double-blindprospectivestudy
and rsceiveda 3-daycourseof AZ(500mg/day)or placebo(P).A fufther
blindedooureeof Azor P wasgivenafter3 monthsto 45 of the original60
patients.Bloodsamplesweretakenat baseline,1,3 and6 monthsandthe
markers measured included monocyte tissue factor (MTF)and CDllb ex-
pression (flow cytometric, MESF unita), total Ieutxqte count (WCC), aerum
naopterin, fibrinogen, Factor Vlla and C-reactive protein levels. No signifi-
cant differences werenotedin anyof the markersin eitherAzor P groupet
baseline,1 or 3 months.At6 monthsthe sub-groupof patientsrandomised
to doubleAz therapy(at baselineandagainat 3 months,GroupAZAZn =
11)showeda significantfall in totalMTFandCDllb comparedto the sub-
groupof patientsreoeivingplacebo(GroupPP,n = 10)only (mean+ SEM,
AMTF:–20.3 + 11.5vs +14.6+ 11.1,p = 0.04;and ACDllb: -2.7 + 1.2
vs+1.6+ 0.9,p = 0.01).RepeatCpserologyat 6 monthsshowedthat5/11
(45%)AZAZpatients(comparedto 0/10PPpatients)hada significantdrop
in Cptitre(p= 0.04).These5 patientsalsohada fall in WCCandneopterin
(neop/creatinine)comparedtothe16patientswithunchangedtitres(AWCC:
-1.2 + 0.6 vs 0.1 + 0.2 x IOg/L,p = 0.05;and Aneop/creat:-3.6+ 2.3va
+0.8?C0.5nmol/umol,p = 0.03).Conclusion:Azithromycintherapyreduces
monocyteactivationandCpantibodyfitresin Post-Mlpatients.Theeffectof








Nimrandil (iV/CJis a potassiumATP-channelactivatorwith a nitrate like
activity Monotherepywith 10 to 20 mg bid of NIC has beenfound to be
efficaciousin stabieanginapaotorispatients.HoweverthetherapywithNIC
is associatedwithsomeincidenceof headacheas othervasodilators.Aim
of our double-blind,parallelgroupstudywasto comparethe incidenceof
adverseevents(AE),andparticularlyof headache,in twodoseregimensof
NICin patients(@) withetableangina.NICwasadministeredfor 6 weeka
in monotherapyat thedoseeof 5, 10,20 mgbid (A)or 10,20,20 mgbid (6I
(2weekaforeachdoseievei).Anadditionalaimof thestudywasto evaluate
efficacyof NICat eachdoseused.Aftera weekof wash-outand a weekof
placeborun-in,172patients(63A-69B)withreproducible xercisetolerance
test(ET7)wererandomised.Every2 weekssafetyandefficacy(ETT)were
